PHS
HRTX icon

PFM Health Sciences’s Heron Therapeutics HRTX Stock Holding History

PFM Health Sciences’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-324,100
Closed -$5.25M – 90
2021
Q1 		$5.25M Buy
+324,100
New +$5.78M 0.16% 79

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

PFM Health Sciences's HRTX Position: Q2 2022 in Review

PFM Health Sciences sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 3,512,348 shares — an estimated $20.1M sold.

PFM Health Sciences first reported a position in HRTX in Q2 2015 and held it in 18 quarters. The position peaked at $74.2M in Q4 2015. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

  • PFM Health Sciences reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
  • PFM Health Sciences sold 3,512,348 Heron Therapeutics shares in Q2 2022, an estimated $20.1M.
  • PFM Health Sciences first reported a position in Heron Therapeutics in Q2 2015 and held it in 18 quarters.
  • PFM Health Sciences's Heron Therapeutics position peaked at $74.2M in Q4 2015.
  • 174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on PFM Health Sciences's 13F filing for Q2 2022, filed 15 Aug 2022.